Annual Meeting 2014: Safety and efficacy of daratumumab with LEN and DEX in relapsed or RRMM

Annual Meeting 2014: Safety and efficacy of daratumumab with LEN and DEX in relapsed or RRMM

577 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Torben Plesner, MD
Department of Hematology, Vejle Hospital
Vejle, Denmark

Daratumumab (DARA) (HuMax-CD38), a human IgG1? monoclonal antibody effectively mediates destruction of CD38-expressing malignant plasma cells. In the first-in-human dose-escalation study, 42% of heavily pretreated patients with relapsed or relapsed, refractory (RR) multiple myeloma (MM) treated with DARA alone (?4mg/kg) achieved partial response (PR) and 25% had minimal response (MR) (modified IMWG guidelines). In preclinical studies, DARA + lenalidomide (LEN) enhanced killing of MM cells in vitro.We evaluated safety, pharmacokinetics (PK) and efficacy of DARA + LEN + dexamethasone (DEX) in patients with relapsed or RR MM.

Visit our website at: http://www.myeloma.org
Up Next Autoplay